To silence LINC01006, specific small interfering RNAs (siRNAs) targeting LINC01006 (si-LINC01006) were devised and synthesized by Shanghai GenePharma Co., Ltd. The si-LINC01006#1 sequence was 5′-CGCAAAGTTTTCCTATTAACTCT-3′; the si-LINC01006#2 sequence was 5′-TTCAAATTTTGACTTATTTTACA-3′; and the si-NC sequence was 5′-CACGATAAGACAATGTATTT-3′. A nonsense sequence (si-NC) was used as the negative control (NC). The miR-28-5p mimic, NC mimic, miR-28-5p inhibitor (anti-miR-28-5p) and NC inhibitor (anti-NC) were obtained from RiboBio Co., Ltd. To overexpress P21-activated kinase 2 (PAK2), the sequences of PAK2 were inserted into the pcDNA3.1 plasmid to obtain the PAK2 overexpression plasmid pcDNA3.1-PAK2 (pc-PAK2; Shanghai GenePharma Co., Ltd.). Cervical cancer cells were cultivated in 6-well plates. As per the manufacturer's instructions, cells were transfected with siRNAs (100 pmol), mimics (100 pmol), miRNA inhibitors (100 pmol) or plasmids (4 μg) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.